The startup is developing oral pharmaceuticals that utilize precision medicine techniques to target the biological mechanisms underlying mental health disorders. By providing personalized treatment options, the company aims to improve patient outcomes in the management of these conditions.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing treatments for mental health disorders often lack personalization, leading to suboptimal outcomes for patients with conditions like major depression. A significant portion of individuals with depression exhibit disruptions in the stress response system, particularly those with a history of adverse experiences, which are not directly addressed by standard antidepressants. This heterogeneity in patient biology necessitates targeted therapies that can address the underlying drivers of symptoms.
Solution
EmbarkNeuro is developing personalized oral pharmaceuticals that target the biological mechanisms underlying mental health disorders, specifically focusing on disruptions in the stress response system. Their lead candidate, ANC-501, is designed to treat depressed individuals with elevated cortisol levels, a biomarker linked to the stress response. By identifying patients with this specific biomarker, EmbarkNeuro aims to match individuals to treatments that address the underlying cause of their symptoms, rather than relying on broad-spectrum antidepressants. This approach seeks to improve treatment efficacy and outcomes for patients with depression and other mental health conditions.
Target Audience
The primary target audience includes individuals with major depression, particularly those with elevated cortisol levels and a history of adverse experiences, as well as the clinicians who treat them.
Features
- ANC-501: A novel oral pharmaceutical specifically designed for depressed individuals with elevated cortisol levels.
- Focus on the stress response system: Targets disruptions in the stress response system, particularly in patients with a history of adverse childhood experiences or traumatic events.
- Biomarker-driven approach: Utilizes biomarkers, such as elevated cortisol, to identify patients who are most likely to benefit from ANC-501.
- Personalized treatment: Aims to match patients to treatments based on the underlying drivers of their symptoms.